Responsive Dual-Targeting Exosome as a Drug Carrier for Combination Cancer Immunotherapy.
Journal
Research (Washington, D.C.)
ISSN: 2639-5274
Titre abrégé: Research (Wash D C)
Pays: United States
ID NLM: 101747148
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
05
2021
accepted:
30
07
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Recently, combination immunotherapy, which incorporates the activation of the immune system and inhibition of immune escape, has been proved to be a new powerful strategy for more efficient tumor suppression compared to monotherapy. However, the major challenge is how to integrate multiple immune drugs together and efficiently convey these drugs to tumor sites. Although a variety of nanomaterials have been exploited as carriers for targeting tumor issues and the delivery of multiple drugs, their potential toxicity, immune rejection, and stability are still controversial for clinical application. Here, we proposed endogenic exosomes as drug carriers to deliver two antibodies acting as tumor-targeting molecules and block checkpoint inhibitors with specific response to the tumor microenvironment and costimulatory molecules for further improvement of therapeutic effect. The versatile exosomes exhibit excellent biocompatibility and provide a combination immunotherapy platform with synergistic advantages of activation of immune response and inhibition of immune escape.
Identifiants
pubmed: 34541546
doi: 10.34133/2021/9862876
pmc: PMC8426567
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9862876Informations de copyright
Copyright © 2021 Yuanyuan Fan et al.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Acta Biomater. 2019 Mar 1;86:1-14
pubmed: 30597259
Adv Sci (Weinh). 2019 Jan 13;6(6):1801847
pubmed: 30937265
J Clin Invest. 2016 Jul 1;126(7):2404-11
pubmed: 27367184
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Nat Nanotechnol. 2019 Mar;14(3):269-278
pubmed: 30664751
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Curr Pharm Biotechnol. 2016;17(9):772-87
pubmed: 26813304
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Biomacromolecules. 2019 Feb 11;20(2):882-892
pubmed: 30621390
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Acta Neuropathol. 2021 Feb;141(2):235-256
pubmed: 33417012
ACS Nano. 2018 Jul 24;12(7):7292-7300
pubmed: 29953205
Nat Rev Cancer. 2012 Mar 22;12(4):237-51
pubmed: 22437869
Mol Pharm. 2019 May 6;16(5):1789-1798
pubmed: 30951627
Angew Chem Int Ed Engl. 2015 Jan 12;54(3):1036-40
pubmed: 25412570
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Br J Pharmacol. 2007 Mar;150(5):552-8
pubmed: 17245366
Nat Rev Drug Discov. 2016 Apr;15(4):235-47
pubmed: 26965203
Nat Nanotechnol. 2017 Aug;12(8):763-769
pubmed: 28459470
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Nat Commun. 2020 Jun 16;11(1):3048
pubmed: 32546688
Adv Drug Deliv Rev. 2016 Mar 1;98:19-34
pubmed: 26546751
Adv Drug Deliv Rev. 2018 Mar 15;128:3-28
pubmed: 28919029
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Angew Chem Int Ed Engl. 2019 Jan 14;58(3):670-680
pubmed: 30016571
Blood. 1985 Mar;65(3):644-8
pubmed: 3971043
ACS Nano. 2009 Jan 27;3(1):16-20
pubmed: 19206243
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Nat Rev Clin Oncol. 2016 May;13(5):273-90
pubmed: 26977780